-
Kicking Opioids For Cannabis? Navigating Kidney Disease Pain Management
Friday, October 13, 2023 - 10:27am | 1095Read More...This article was originally published on The Fresh Toast and appears here with permission Although there are different diseases and medical conditions that take people’s lives, in the US kidney disease is the ninth leading cause of death. It’s also estimated that 31 million...
-
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
Saturday, December 31, 2022 - 12:11pm | 1490Read More...2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like Apple Inc. (NASDAQ: AAPL) and Tesla Inc. (NASDAQ: TSLA) bit the dust, there were a...
-
Novartis Stops Iscalimab Trial In Kidney Transplant Patients
Friday, September 3, 2021 - 7:09am | 194Read More...Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection. Iscalimab's study in liver transplant...
-
Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate
Monday, August 16, 2021 - 7:57am | 191Read More...Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of treatment. After 36 weeks of treatment, patients receiving sparsentan achieved a mean...
-
Regulus's Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis
Friday, May 21, 2021 - 10:47am | 267Read More...Regulus Therapeutics Inc (NASDAQ: RGLS) has announced an incremental update from the first cohort of patients from its ongoing Phase 1b trial evaluating RGLS4326 in Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic disorder characterized by the growth of...
-
Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study
Monday, May 3, 2021 - 9:25am | 373Read More...Regulus Therapeutics Inc (NASDAQ: RGLS) has announced top-line results from the first cohort of patients (n=9) with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in its ongoing Phase 1b trial of RGLS4326. The study evaluates the safety, pharmacokinetics, and effects on...
-
AstraZeneca's Diabetes Drug Farxiga Scores FDA Nod In Kidney Disease
Monday, May 3, 2021 - 7:41am | 229Read More...The FDA has approved AstraZeneca plc's (NASDAQ: AZN) Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 inhibitor, to treat chronic kidney disease (CKD) even in patients without diabetes. Under the new approval, Farxiga can be used to reduce the risk of declining...
-
Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services
Thursday, April 22, 2021 - 7:58am | 188Read More...Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. The contract, offered through the General Services Administration, covers...
-
Calliditas Starts Dosing In Nefecon Open Label Extension Study In Kidney Disease
Thursday, February 4, 2021 - 9:05am | 317Read More...Calliditas Therapeutics AB (NASDAQ: CALT) has dosed that first patient in the global open-label extension part of Phase 3 study (dubbed as NefIgArd) that will offer a 9-month treatment with Nefecon to all qualifying patients who have completed the NefIgArd study and will...
-
Chinook Therapeutics Nabs Rare Pediatric Disease Tag For CHK-336 In Primary Hyperoxaluria
Tuesday, February 2, 2021 - 12:23pm | 211Read More...The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Inc's (NASDAQ: KDNY) CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxaluria (PH), a rare genetic disorder that mainly affects the kidneys...
-
3 Companies Filed For Chapter 11 Bankruptcy Today
Monday, May 2, 2016 - 1:44pm | 523Read More...Monday's trading action featured at least three companies filing for Chapter 11 bankruptcy. NephroGenex NephroGenex Inc (NASDAQ: NRX), a pharmaceutical company that focuses on the development of treatment for kidney disease, announced it has filed a voluntary petition under Chapter 11 of...
-
Akebia Therapeutics Lower Following Announcement Of Public Offering, Corporate And Clinical Developments
Tuesday, January 5, 2016 - 10:03am | 297Read More...Shares of Akebia Therapeutics Inc (NASDAQ: AKBA), a biopharmaceutical company that focuses on products for the treatment of kidney diseases, were trading lower by around 0.5 percent early Tuesday morning after the company announced it plans on offering and selling $75 million worth of its...
-
Thanks, FDA: NephroGenex Investors Rejoice After New Clearance
Monday, December 14, 2015 - 1:52pm | 313Read More...NephroGenex Inc (NASDAQ: NRX), the pharma company focused on the development of therapeutics to treat kidney disease, is soaring by 68.05 percent to $2.42 on Monday. The astronomical move follows the company's announcement of FDA clearance for IND Application for clinical study of Intravenous...
